26 results about "Thrombolytic Agent" patented technology

The invention relates to the technical field of thrombus mining robots, in particular to a micron robot with an asymmetric cilia structure, a preparation method and application. The micro-robot is of an asymmetric composite structure and is composed of a smooth hemisphere and a cilia-shaped structure, sandwich type layered arrangement of a PLGE cilia-shaped nano structure, an MNPs interlayer and a PS sphere core is formed on the surface and the interior of the micro-robot from outside to inside, and cooperative regulation and control of morphology and functions are achieved by regulating and controlling the material proportion of PS and PLGE. The thrombus mining robot shows an efficient thrombolysis effect in a plurality of in-vitro and in-vivo models, and rapid fibrinolysis, deep thrombus penetration and efficient mining of single red blood cells are realized, so that the limitation of a traditional thrombolysis agent is overcome. In addition, the thrombus digging robot has excellent biocompatibility and biological safety, has no obvious cytotoxicity or damage to main organs, and supports the safety of the thrombus digging robot in clinical application.

The invention discloses a PAI-1 protein targeting peptide compound (called P peptide for short) with a thrombus dissolving effect and application thereof, and belongs to the field of biological medicine. The PAI-1 targeted thrombolytic polypeptide compound comprises P1, P2, P3 and P4, and is characterized in that the compound is derived from a core structure 'X-Asp-Glu-Leu-Cys-X-Tyr-Tyr-X-X-Cys-X' (cyclization is performed through a disulfide bond between Cys, and X represents any type of amino acid), and the compound can be specifically bound with a key binding site of PAI-1. The polypeptide can significantly reduce the inhibitory effect of PAI-1 on plasminogen activators (tPA, uPA), enhance the activity of a fibrinolytic system, and generate in-vivo and in-vitro thrombolysis effects. The polypeptide compounds P1, P2, P3 and P4 not only have a thrombolysis effect, but also can reduce the expression level of pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6 and the like), which shows that the polypeptide compounds also have an anti-inflammatory effect. In conclusion, the polypeptide compound can be used for preparing a PAI-1 antagonist, a thrombolytic agent and an anti-inflammatory agent related to thrombus.

The invention discloses a nerve intervention thrombectomy and thrombolysis device and belongs to the technical field of nerve thrombectomy, the nerve intervention thrombectomy and thrombolysis device comprises a guider and a puncture tube connected to the guider in a penetrating mode, one side of the guider is connected with a guiding tube in a penetrating mode, and the guiding tube is arranged at the center position of the puncture tube in a penetrating mode; the other side of the guider is connected with a central tube in a penetrating mode, a positioning hole is formed in the guiding tube, and the central tube is connected to the central position of the guiding tube in a penetrating mode through the positioning hole. The diameter of the central tube is smaller than that of the guide tube; a positioning mechanism which assists the central tube and the guide tube in penetrating connection is arranged in the guider; when the thrombus taking and thrombolysis device is used, the central tube can be quickly and accurately connected into the guide tube in a penetrating manner, so that a thrombolysis medicament can accurately act on blocked thrombus, and the thrombus taking and thrombolysis treatment effect is improved.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the SUR1-TRPM4 channel inhibitor is used in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤ 20. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.

A method for the treatment of thromboembolism comprising administering a thrombolytic agent directly to the thromboembolism in the presence of ultrasound. The total dose of thrombolytic agent administered is between 1 and 12 mg and the time over which the total dose is delivered is less than 15 hours.

A method of removing vascular blockage includes providing a catheter system, comprising an outer catheter, a bypass catheter, and a guidewire. In the catheter system, the bypass catheter is slidably disposed within the outer catheter. The method includes positioning a distal end of the catheter system at a proximal end of an occlusion located within a vessel and moving the bypass catheter through the occlusion so that a medicated treatment solution may be delivered through the bypass catheter to an area of the brain or other tissue served by the vessel blocked by the occlusion. Both during and after the delivery of medicated treatment solution to the blocked part of the vessel with the bypass catheter, the physician may engage the occlusion with the perforated segment of the outer catheter so that a thrombolytic agent can be delivered at the occlusion to disintegrate it and then removing at least a portion of the occlusion from the vessel.

The invention relates to an antithrombotic catheter. The antithrombotic catheter comprises a hydrogel coating containing a thrombolytic agent. The thrombolytic agent may be a lyophilized tissue plasminogen activator. The catheter has an inner lumen surface and an outer lumen surface, and a hydrogel coating is disposed on the inner lumen surface and / or the outer lumen surface. The hydrogel coating may have a thickness in the range of about 50 nm to about 150 nm. The hydrogel coating may contain from about 0.1 wt% to about 1 wt% of a tissue plasminogen activator. The hydrogel coating may be made from a synthetic hydrogel or a natural hydrogel. Presently preferred synthetic hydrogels include polyacrylamide based hydrogels. Presently preferred natural hydrogels include hyaluronic acid based hydrogels. The hydrogel coating reacts in the presence of a physiological liquid to absorb water and elute the solvating suppository. The hydrogel controls elution of the thrombolytic agent. Examples of physiological fluids include interstitial fluids and blood.

Provided is a thrombolytic agent for ‘intravascular thrombus’, and more particularly, to a thrombolytic agent having a thrombo-recognition domain and a thrombolytic domain. It also relates to a polypeptide for thrombolysis of an intravascular thrombus, a gene for that polypeptide, and a pharmaceutical composition containing the same. The polypeptide that recognizes ‘intravascular thrombus’ and dissolves thrombus of the present invention is characterized in that it consists of a thrombolytic domain comprising the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 and a thrombo-recognition domain comprising the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4. According to the present invention, the polypeptide for dissolving thrombus by recognizing ‘intravascular thrombus’ dissolves thrombus in the blood of a mammal without serious bleeding side effects has a preventive and therapeutic effect on thrombosis, thus preventing thrombosis and related diseases.

This disclosure relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤20. In other embodiments, patients have lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the SUR1-TRPM4 channel inhibitor is used in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤ 20. In certain embodiments, patients have a lesion volume of less than 300 cm3, less than 140 cm3, or less than 125 cm3 as measured by MRI DWI or CTP. In certain embodiments, patients have a lesion volume expanding at a rate or < 25 mL / h. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.

The invention discloses a dimer of R, R-heptacyclic dimethyl acetal in the following formula, namely [R, R-heptacyclic dimethyl acetal] 2, and discloses a preparation method of the dimer and application of the dimer as a thrombolytic agent in treatment of thrombotic diseases. Experiments prove that the [R, R-heptacyclic dimethyl acetal] 2 disclosed by the invention not only has a good thrombolysis effect, but also has the thrombolysis effect significantly stronger than that of the R, R-heptacyclic dimethyl acetal. Therefore, the invention provides an effective technical means for thrombolysis in treatment of thrombotic diseases. # imgabs0 #

The present invention provides an ultrasonic perfusion thrombolysis device. It includes: a perfusion support, at least one ultrasonic module for outputting ultrasonic waves, and a control component; the perfusion support includes a plurality of perfusion tubes for constructing the perfusion support, and the plurality of perfusion tubes extend along the circumference and axial direction of the perfusion support, and any perfusion tube has a perfusion tube section with a plurality of perfusion holes; at least one ultrasonic module is respectively arranged in the perfusion tube and extends along the perfusion tube section, and the ultrasonic module can expand and contract together with the perfusion support; the control component is connected to the perfusion support at the far end, and is used to accommodate the perfusion support in a contracted state and release the perfusion support, and is also used to control the expansion and contraction state of the perfusion support; the control component is also electrically connected to the ultrasonic module, and is used to provide a driving signal for the ultrasonic module. The perfusion tube of the perfusion support is used to perfuse the thrombolytic agent while providing ultrasonic waves to accelerate thrombolysis, which can effectively improve the thrombolysis efficiency, greatly reduce the dosage of the agent, and reduce the risk of bleeding.

This invention discloses a sonodynamic synergistic thrombolysis system and its application. The system includes a tissue plasminogen activator variant, a sonosensitive agent, and an ultrasound source. The tissue plasminogen activator variant is an intravenously administered formulation, the sonosensitive agent is an intravenously infused formulation, and the ultrasound source is used to emit ultrasound during sonosensitive agent administration to activate the agent. This invention significantly improves thrombolysis efficiency and reduces thrombolytic agent dosage and bleeding risk through the dual synergistic effect of TNK-tPA enzymatic hydrolysis and sonodynamic chemical oxidation. The system can significantly improve vascular recanalization rate and blood flow velocity recovery rate, and has high biocompatibility. This invention is applicable to thrombolytic treatment of various thrombotic diseases and has the advantages of simple operation, strong targeting, and wide application range.

The present invention provides engineered plasmin variants and related compositions that are resistant to inhibition of plasmin protease activities by plasmin inhibitors, which can be used as direct-acting thrombolytic agents in the treatment of thrombosis and thrombotic disorders.

The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent comprising a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement, and wherein therapeutic agent is administered in combination with rehabilitation therapy or thrombolytic agent.

To provide the treatment of ischemic stroke at risk of brain swelling using a SUR1-TRPM4 channel inhibitor.SOLUTION: In some embodiments, the method comprises treating a patient suffering from a large hemispheric infarction. In certain embodiments, the patient has a baseline NIHSS≤20. In other embodiments, the patient has a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo thrombolytic therapy and / or decompressive therapy.SELECTED DRAWING: None

This invention provides a thrombolysis catheter structure and an interventional device for thrombosis treatment, relating to thrombosis treatment medical devices. The device includes a thrombolysis catheter and a thrombolysis head. The proximal end of the thrombolysis catheter is connected to an ultrasonic transducer to receive vibrational energy. The thrombolysis catheter also has a first inlet for introducing thrombolytic agents. The thrombolysis head is fixedly connected to the distal end of the thrombolysis catheter, and the diameter of the thrombolysis head is larger than the diameter of the thrombolysis catheter. The thrombolysis head has a drug chamber that communicates with the distal end of the thrombolysis catheter. The thrombolysis head also has a spray hole communicating with the drug chamber, facing distally. This invention enables simultaneous ultrasonic thrombolysis and drug thrombolysis, allowing mechanical thrombolysis and drug thrombolysis to act simultaneously on the same area of ​​the thrombus, significantly improving thrombosis treatment efficiency. Furthermore, since thrombolysis and thrombolysis are performed concurrently, there is no need to change surgical instruments multiple times to perform the thrombolysis and thrombolysis processes separately, which helps to shorten the operation time.

Provided is a thrombolytic agent for ‘intravascular thrombus’, and more particularly, to a thrombolytic agent having a thrombo-recognition domain and a thrombolytic domain. It also relates to a polypeptide for thrombolysis of an intravascular thrombus, a gene for that polypeptide, and a pharmaceutical composition containing the same. The polypeptide that recognizes ‘intravascular thrombus’ and dissolves thrombus of the present invention is characterized in that it consists of a thrombolytic domain comprising the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 and a thrombo-recognition domain comprising the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4. According to the present invention, the polypeptide for dissolving thrombus by recognizing ‘intravascular thrombus’ dissolves thrombus in the blood of a mammal without serious bleeding side effects has a preventive and therapeutic effect on thrombosis, thus preventing thrombosis and related diseases.

A method of removing vascular blockage includes providing a catheter system, comprising an outer catheter, a bypass catheter, and a guidewire. In the catheter system, the bypass catheter is slidably disposed within the outer catheter. The method includes positioning a distal end of the catheter system at a proximal end of an occlusion located within a vessel and moving the bypass catheter through the occlusion so that a medicated treatment solution may be delivered through the bypass catheter to an area of the brain or other tissue served by the vessel blocked by the occlusion. Both during and after the delivery of medicated treatment solution to the blocked part of the vessel with the bypass catheter, the physician may engage the occlusion with the perforated segment of the outer catheter so that a thrombolytic agent can be delivered at the occlusion to disintegrate it and then removing at least a portion of the occlusion from the vessel.

The present invention belongs to the technical field of biomedical materials, and specifically relates to an indane isomer photothermal thrombolytic agent, a preparation method thereof, and an application thereof. The indane isomer photothermal thrombolytic agent is co-assembled by an organic small molecule and a thrombus fusion protein peptide; the organic small molecule is 1,3-bis(dicyanomethylene)indane isomer 6DNMDD or 4DNMDD. The indane isomer photothermal thrombolytic agent obtained by the present invention has excellent photothermal conversion efficiency on the one hand, and thrombus homing ability on the other hand. When treating lower extremity artery and carotid artery embolism, 4DNMDD-C NPs exhibit higher photothermal conversion efficiency and photoacoustic imaging ability, and have better diagnostic and therapeutic effects.

The invention discloses a thrombus aspiration thrombolysis protection method, and relates to the technical field of medical equipment. The method comprises the following steps: S1, injection subcutaneous anesthesia; S2, thrombus suction; and S3, thrombus thrombolysis. According to the thrombus aspirator, through cooperation of the flow channel control assembly, the push-pull mechanism and the power switching assembly, the flow channel control assembly controls opening and closing of the cavity channel, the power switching assembly controls the push-pull mechanism to act on the aspiration tank or the injection tank, and in the thrombus aspiration process, thrombus can be aspirated into the aspiration tank through a piston disc in the push-pull mechanism; in the thrombus thrombolysis process, a thrombolysis medicament in the injection tank can be extruded through the piston disc in the push-pull mechanism, and the thrombolysis medicament is injected into a thrombus section of a blood vessel through the catheter, so that thrombus suction and thrombolysis operations in the thrombus treatment process are conveniently realized, and the convenience of the thrombus suction operation and the thrombolysis operation is effectively improved; and the operation intensity of medical personnel is reduced.

To provide the treatment of ischemic stroke at risk of brain swelling using a SUR1-TRPM4 channel inhibitor.SOLUTION: In some embodiments, the method comprises treating a patient suffering from a large hemispheric infarction. In certain embodiments, the patient has a baseline NIHSS≤20. In other embodiments, the patient has a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo thrombolytic therapy and / or decompressive therapy.SELECTED DRAWING: None

A protease-resistant ADAMTS13 mutant protein or nucleic acid encoding the ADAMTS13 mutant protein is provided. The ADAMTS13 mutant protein comprises a mammalian ADAMTS13 protein in which one or more protease cleavage sites within the protein are replaced with amino acid sequence that is resistant to protease cleavage, and the mutant protein retains von Willebrand factor (VWF)-cleaving activity. The protease-resistant ADAMTS13 mutant is useful as a thrombolytic agent to treat common thrombotic disorders, including stroke, myocardial infarction, venous thromboembolism, and rare microvascular thrombotic disorders like thrombotic thrombocytopenia purpura (TTP).

Crosslinked polysaccharide nanoparticles The present invention relates to cross-linked polysaccharide nanoparticles, which can be used as drug delivery systems. The herein disclosed cross-linked polysaccharide nanoparticles are obtained via an emulsion cross-linking process. The careful choice of the surfactants used for forming the emulsion allows to reliably obtain small particles with a low polydispersity. Moreover, these particles are stable in saline solutions. The cross-linked polysaccharide nanoparticles can be loaded with proteinaceous fibrinolytic or thrombolytic agents and could be used as drug delivery systems for the treatment of thrombosis.

A method for the treatment of thromboembolism comprising administering a thrombolytic agent directly to the thromboembolism in the presence of ultrasound. The total dose of thrombolytic agent administered is between 1 and 12 mg and the time over which the total dose is delivered is less than 15 hours.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the SUR1-TRPM4 channel inhibitor is used in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤ 20. In certain embodiments, patients have a lesion volume of less than 300 cm3, less than 140 cm3, or less than 125 cm3 as measured by MRI DWI or CTP. In certain embodiments, patients have a lesion volume expanding at a rate or < 25 mL / h. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.